LEADER 00926nam0-22003491i-450 
001 990000847510403321
005 20180925122940.0
010   $a2-04-004476-0
035   $a000084751
035   $aFED01000084751
035   $a(Aleph)000084751FED01
035   $a000084751
100   $a20001010d1973----km-y0itay50------ba
101 0 $afre
105   $ay-------001yy
200 1 $aStatistique$eexercices corrigés$fpar C. Labrousse
205   $a3. ed.
210   $aParis$cDunod$d1973
215   $a3 v. 24 cm
225 1 $aMathématique et statistique de l'économie
327 1 $a2: XII, 354 p.
676   $a519.5
700  1$aLabrousse,$bChristian$040825
801  0$aIT$bUNINA$gRICA$2UNIMARC
901   $aBK
912   $a990000847510403321
952   $a02 29 B 31$b1427$fFINBN
952   $a02 31 B 1$b1786$fFINBN
959   $aFINBN
996   $aStatistique$9348400
997   $aUNINA
DB    $aING01

LEADER 01572nam  2200529   450 
001 9910495172503321
005 20230717103733.0
010   $a3-030-85067-6
035   $a(CKB)5600000000003435
035   $a(MiAaPQ)EBC6715884
035   $a(Au-PeEL)EBL6715884
035   $a(PPN)257351051
035   $a(EXLCZ)995600000000003435
100   $a20220608d2021      uy             0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aNanoparticles for rational vaccine design /$fHarvinder Singh Gill, Richard W. Compans, editors
210  1$aCham, Switzerland :$cSpringer,$d[2021]
210  4$d©2021
215   $a1 online resource (140 pages)
225 1 $aCurrent topics in microbiology and immunology ;$v433
311   $a3-030-85066-8 
410  0$aCurrent topics in microbiology and immunology ;$v433.
606   $aVaccines$xDesign
606   $aVacunes$2thub
606   $aImmunoteràpia$2thub
606   $aNanopartícules$2thub
606   $aNanomedicina$2thub
608   $aLlibres electrònics$2thub
615  0$aVaccines$xDesign.
615  7$aVacunes
615  7$aImmunoteràpia
615  7$aNanopartícules
615  7$aNanomedicina
676   $a615.372
702   $aGill$b Harvinder Singh
702   $aCompans$b Richard W.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910495172503321
996   $aNanoparticles for Rational Vaccine Design$92196231
997   $aUNINA